Schwab Network 对 $HIMS 的判断变化

频道资料 →频道引用的来源:BFA and JP Morgan、Baird、Bank of America、Barclays、Berenberg、Bernstein、Bernstein, with a Jefferies target cut noted、Bilal Little、Bird (analyst firm)、CEO、CEO Joe Dominguez、Caner、Citi、Citigroup、Citizens、Daiwa、Dan Deming and Michael Monahan、Dan Ies; Morgan Stanley、Dan Ives、Dan Ives and unnamed analysts、Deutsche Bank、Erit Research、Evercore ISI、Evercore ISI; Dan Ives、Goldman Sachs、JP Morgan Chase、JPMorgan、JPMorgan Chase、James Demerard of Wall Street Research、Jefferies、Jefferies, UBS and Citigroup、Jensen Huang; Dan Ives、KeyBank、Loop Capital、Mattie Natsson、Michael Saylor、Milius (analyst)、Morgan Stanley、Northrop、Oppenheimer、Oppenheimer, Freedom Broker、Oracle、PFA analysts、Quantum CEO、RBC、Reddit CEO、Rothschild Redburn、SK Hynix、Seth、Tim Bigham、Tim and KG、Truist、UBS、Wall Street Journal、Wedbush、Wells Fargo、analysts、the street共 3 条

Schwab Network 自 2026-09-18 起在 3 个视频里谈过 $HIMS。

2026-11-18
《Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed》
AI 摘要 · HIMS 推出 Peptides Plus,包含五种联合疗法,有望在肽类需求上升之际吸引传统远程医疗之外的新客户并带来经常性收入;但首批疗法均未获 FDA 批准,HIMS 表示安全性、有效性和剂量仍不确定,监管与科学风险可能实质性威胁其增长计划。

Hims&Hers 可能错过了“多肽热潮之夏”,但随着它推出新的“Peptides Plus”平台,提供五种组合疗法,针对从精力与恢复到细胞健康的各种需求,一个“多肽热潮之冬”可能即将到来。

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

这一举措出台之际,多肽的需求正在上升,但这里存在一个重大障碍。最初的治疗方案均未获得美国食品药品监督管理局(FDA)的批准,公司自己也承认,关于其安全性、有效性和合适剂量,仍有很多需要了解。

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

2026-11-10
《HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus》
AI 摘要 · 在意外亏损、营收与订阅用户数双双不及预期、指引低于市场共识之后,HIMS 下跌 13.5% 至约 19 美元,年初至今跌幅接近 40%。说话者预计其将在当前水平附近企稳,20 美元为主要支撑位,并卖出一份 12 月虚值看跌期权价差;他认为增长将持续但放缓,肽类业务的利好正在消退,两位数增长可能已经结束,但公司本身依然稳健。

我们来看一下 Hims and Hers 的走势图。这家医疗健康公司本季度意外转为亏损,并收窄了全年销售展望,股价因此承压。

Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.

这是我们在一年走势图上看到的情况。它已经回落了相当多。Hims and Hers 目前下跌约13.5%,股价在19美元出头。所以这是今天早盘交易的焦点。

So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.

2026-09-18看涨
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
订阅或试用后可见这一步的正文
更早的 1 条正文需要订阅
最近 2 条的正文公开可读。更早的条目保留日期与方向,正文随订阅解锁。
订阅后阅读全部 1 条更早的观点